Aclaris Therapeutics (NASDAQ:ACRS) reported quarterly losses of $(0.15) per share which met the analyst consensus estimate. This is a 25 percent decrease over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $1.996 million which beat the analyst consensus estimate of $1.322 million by 51.02 percent. This is a 37.18 percent increase over sales of $1.455 million the same period last year.